Breakthroughs in IPF may lead to first approval in years

23 September 2025

After years of limited progress, new treatments for idiopathic pulmonary fibrosis (IPF) are moving closer to approval, according to a new review from pharma analytics firm GlobalData.

German family-owned drug major Boehringer Ingelheim’s nerandomilast has shown strong Phase III results and could secure approval later in 2025, while United Therapeutics’ (Nasdaq: UTHR) inhaled treprostinil advances in late-stage trials, signaling a potential breakthrough for patients facing this debilitating lung disease, says GlobalData.

The pharmaceutical industry currently focuses on developing the next generation of IPF therapies, with several companies currently standing out. Such companies include Boehringer, already known for its anti-fibrotic drug Ofev (nintedanib), and now leading the pipeline with nerandomilast, which has recently concluded a successful Phase III clinical trial (FIBRONEER-IPF), demonstrating significant slowing of lung function decline in IPF patients compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK